×
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)

Annexon Stock Forecast, Price & News

$3.82
-0.07 (-1.80%)
(As of 07/5/2022 11:37 AM ET)
Add
Compare
Today's Range
$3.82
$4.00
50-Day Range
$2.48
$4.06
52-Week Range
$2.06
$23.81
Volume
1,455 shs
Average Volume
593,804 shs
Market Capitalization
$147.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.75

Annexon MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
754.8% Upside
$33.25 Price Target
Short Interest
Bearish
8.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$147,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.76) to ($3.49) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.23 out of 5 stars

Medical Sector

250th out of 1,428 stocks

Pharmaceutical Preparations Industry

122nd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ANNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter.

Annexon logo

About Annexon (NASDAQ:ANNX) Stock

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX Stock News Headlines

Some Biotech Stocks Are Now Cheap
Why Annexon Biosciences Stock Plummeted 34% Today
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANNX
Employees
61
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/05/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$33.25
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+835.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-130,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.04 per share

Miscellaneous

Free Float
35,286,000
Market Cap
$147.30 million
Optionable
Not Optionable
Beta
0.22














Annexon Frequently Asked Questions

Should I buy or sell Annexon stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Annexon stock.
View analyst ratings for Annexon
or view top-rated stocks.

What is Annexon's stock price forecast for 2022?

5 Wall Street analysts have issued 12-month price objectives for Annexon's stock. Their ANNX stock forecasts range from $24.00 to $40.00. On average, they predict Annexon's share price to reach $33.25 in the next year. This suggests a possible upside of 761.4% from the stock's current price.
View analysts' price targets for Annexon
or view top-rated stocks among Wall Street analysts.

How has Annexon's stock performed in 2022?

Annexon's stock was trading at $11.49 at the beginning of 2022. Since then, ANNX stock has decreased by 66.4% and is now trading at $3.86.
View the best growth stocks for 2022 here
.

When is Annexon's next earnings date?

Annexon is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Annexon
.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) issued its quarterly earnings results on Monday, May, 9th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. The business earned $32 million during the quarter. The firm's revenue was up 166.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.68) earnings per share.
View Annexon's earnings history
.

Who are Annexon's key executives?

Annexon's management team includes the following people:
  • Mr. Douglas Love J.D., Esq., CEO, Pres & Director (Age 54, Pay $830.99k) (LinkedIn Profile)
  • Dr. Larry Mattheakis Ph.D., Exec. VP & Chief Scientific Officer (Age 65, Pay $296.45k)
  • Dr. Ted Yednock Ph.D., Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board (Age 64, Pay $614.6k)
  • Dr. Arnon Rosenthal Ph.D., Founder (Age 66)
  • Ms. Jennifer Lew, Exec. VP & CFO (Age 49) (LinkedIn Profile)
  • Miriam Mason, Sr. VP of Corp. Communications
  • Mr. Michael Overdorf M.B.A., Exec. VP & Chief Bus. Officer (Age 52)
  • Henk-Andre Kroon M.D., Sr. VP of Translational Medicine
  • Mirella Villa Del Toro, Sec.

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include (HON), Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE).

When did Annexon IPO?

(ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO.

What is Annexon's stock symbol?

Annexon trades on the NASDAQ under the ticker symbol "ANNX."

How do I buy shares of Annexon?

Shares of ANNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annexon's stock price today?

One share of ANNX stock can currently be purchased for approximately $3.86.

How much money does Annexon make?

Annexon (NASDAQ:ANNX) has a market capitalization of $148.84 million. The company earns $-130,320,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis.

How many employees does Annexon have?

Annexon employs 61 workers across the globe.

How can I contact Annexon?

The official website for Annexon is www.annexonbio.com. The company can be reached via phone at 650-822-5500, via email at swheeler@wheelhouselsa.com, or via fax at 650-636-9773.

This page (NASDAQ:ANNX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.